Search Results - "Lentz, Robert William"

Risk factors for the development of atrial fibrillation on ibrutinib treatment by Lentz, Robert William, Ma, Shuo, Akhter, Nausheen

“…Abstract only…”
Get full text

Understanding the efficacy of frontline therapies for hepatocellular carcinoma through etiologic stratification by Goryachok, Maksym, Hu, Junxiao, Lentz, Robert William, Messersmith, Wells A., Leal, Alexis Diane, Kim, Sunnie S., Baiyee Toegel, Emily, Lieu, Christopher Hanyoung, Davis, S. Lindsey

“…491 Background: Despite significant advancements in recent years, hepatocellular carcinoma (HCC) treatment options remain limited for patients who progress on…”
Get full text

Disparities and trends in biomarker testing in metastatic colorectal cancer by Robinson, Hannah Ruth, Hu, Junxiao, Balmaceda, Nicole Baranda, Lentz, Robert William, Baiyee Toegel, Emily, Leal, Alexis Diane, Kim, Sunnie S., Messersmith, Wells A., Lieu, Christopher Hanyoung, Davis, S. Lindsey

“…29 Background: Several therapies with biomarker-based indications have received approvals for use in metastatic colorectal cancer (mCRC) in the past decade…”
Get full text

Real-world analysis of irinotecan (iri) with or without fluorouracil (5FU) in the second line treatment (2L) of metastatic colorectal cancer (mCRC) by Lentz, Robert William, Hu, Junxiao, Robinson, Hannah Ruth, Balmaceda, Nicole Baranda, Baiyee Ebot, Emily Eyoung, Leal, Alexis Diane, Kim, Sunnie S., Davis, S. Lindsey, Messersmith, Wells A., Lieu, Christopher Hanyoung

“…102 Background: The most used 1 st line (1L) chemotherapy backbone for mCRC is fluoropyrimidine (FP) + oxaliplatin. In the 2L, iri alone or with 5FU (FOLFIRI),…”
Get full text

Impact of early-onset colorectal cancer on utilization of chemotherapy and outcomes in patients with stage II disease by Leary, Jacob Beck, Hu, Junxiao, Davis, Sean, Leal, Alexis Diane, Davis, S. Lindsey, Kim, Sunnie S., Lentz, Robert William, Friedrich, Tyler, Vogel, Jon, Herter, Whitney, Chapman, Brandon C., Messersmith, Wells A., Lieu, Christopher Hanyoung

“…85 Background: Rising rates of early-onset colorectal cancer (EOCRC) pose a dilemma for clinicians when deciding how to treat early-stage patients to maximize…”
Get full text

Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01) by Lentz, Robert William, Hu, Junxiao, Blatchford, Patrick Jud, Pitts, Todd, Leal, Alexis Diane, Kim, Sunnie S., Davis, S. Lindsey, Lieu, Christopher Hanyoung, Scott, Aaron James, Boland, Patrick M, Hochster, Howard S., Messersmith, Wells A.

“…TPS257 Background: Refractory microsatellite stable colorectal cancer (MSS CRC) is immunologically cold and single-agent anti-PD-1/PD-L1 drugs are ineffective;…”
Get full text

Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers by Lentz, Robert William, Friedrich, Tyler, Hu, Junxiao, Leal, Alexis Diane, Kim, Sunnie S., Davis, S. Lindsey, Purcell, Tom, Messersmith, Wells A., Lieu, Christopher Hanyoung

“…Abstract only e14559 Background: While TMB is very dependent on methodology, tissue TMB-H (≥10 mutations/megabase) may predict benefit with ICIs. Pembrolizumab…”
Get full text

Incidence of nonvalvular atrial fibrillation on ibrutinib compared to other tyrosine kinase inhibitors: A large multi-institution general practice study by Njoroge, Joyce, Lentz, Robert William, Linares, Jered, Gans, Christopher, Akhter, Nausheen

“…Abstract only…”
Get full text

Clinical implication of monitoring PD-L1+ circulating tumor cells (CTCs) in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy by Hoffmann, Andrew Daniel, Davis, Andrew A., Iams, Wade Thomas, Oh, Michael S, Lentz, Robert William, Chae, Young Kwang, Liu, Huiping

“…Abstract only e14044 Background: CTCs not only constitute a cellular component of liquid biopsy for dynamic, longitudinal information of malignancies, but also…”
Get full text

A phase II study of pembrolizumab, binimetinib, and bevacizumab in patients with microsatellite-stable, refractory, metastatic colorectal cancer (mCRC) by Friedrich, Tyler, Blatchford, Patrick Jud, Lentz, Robert William, Davis, S. Lindsey, Kim, Sunnie S., Leal, Alexis Diane, Van De Voorde, Zoe, Lee, Matthew R, Waring, Meredith, Cull, Tiffany, Martin, Anne, Eckhardt, S. Gail, Messersmith, Wells A., Lieu, Christopher Hanyoung

“…Abstract only 118 Background: To date, immune-checkpoint inhibition for microsatellite stable (MSS) mCRC has been ineffective, though targeted therapy…”
Get full text

Utility of chemotherapy given before and/or after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases by Friedrich, Tyler, Hu, Junxiao, Lentz, Robert William, Leal, Alexis Diane, Kim, Sunnie S., Messersmith, Wells A., Davis, S. Lindsey, McCarter, Martin, Ahrendt, Steven Arthur, Gleisner, Ana, Lieu, Christopher Hanyoung

“…Abstract only e16276 Background: Appendiceal adenocarcinoma is relatively rare and often diagnosed incidentally during operations for acute appendicitis. It is…”
Get full text

A single-institution experience using total neoadjuvant therapy to treat locally advanced rectal cancer by Friedrich, Tyler, Glode, Ashley Elizabeth, Lentz, Robert William, Herter, Whitney, Davis, S. Lindsey, Leal, Alexis Diane, Kim, Sunnie S., Purcell, William T., Ahrendt, Steven Arthur, Birnbaum, Elisa, McCarter, Martin, Gleisner, Ana, Schefter, Tracey E., Vogel, Jon, Messersmith, Wells A., Lieu, Christopher Hanyoung

“…Abstract only 64 Background: The management of locally advanced rectal cancer has historically included preoperative chemoradiation followed by surgery and…”
Get full text

Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors by Davis, Andrew A., Iams, Wade Thomas, Chan, David, Oh, Michael S, Lentz, Robert William, Peterman, Neil, Robertson, Alex, Shah, Abhik, Srivas, Rohith, Lambert, Nicole, Wilson, Timothy, George, Peter, Wong, Becky, Tezcan, Ayse, Yalamanchili, Ram, Nesmith, Ken, Spinosa, John C, Tezcan, Haluk, Chae, Young Kwang

“…Abstract only 3041 Background: Liquid biopsies have potential clinical utility as dynamic biomarkers for treatment response. We analyzed serial changes in…”
Get full text

A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment by Davis, Andrew A., Iams, Wade Thomas, Chan, David, Oh, Michael S, Lentz, Robert William, Srivas, Rohith, Lambert, Nicole, Robertson, Alex, Peterman, Neil, Shah, Abhik, Wilson, Timothy, Close, Jason, George, Peter, Wood, Haleigh, Tezcan, Ayse, Yalamanchili, Ram, Nesmith, Ken, Spinosa, John C, Tezcan, Haluk, Chae, Young Kwang

“…Abstract only 3042 Background: Methylation is an epigenetic modification linked to cancer pathogenesis. The aim was to determine if changes in cfDNA…”
Get full text